R. Klinghoffer

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Rich Klinghoffer, R A Klinghoffer, Richard A Klinghoffer, R. Klinghoffer, Rich A Klinghoffer, R.a. Klinghoffer, Richard Klinghoffer, Richard A. Klinghoffer, R Klinghoffer
Publication record
65 papers · 3,663 citations · H-index 22

PAPERS

In Situ Proinflammatory Effects of Dazostinag Alone or with Chemotherapy on the Tumor Microenvironment of Patients with Head and Neck Squamous Cell Carcinoma
20250 citationsauthor #15
Early, precise, and safe clinical evaluation of the pharmacodynamic effects of novel agents in the intact human tumor microenvironment
20242 citationsauthor #34
Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
202319 citationsauthor #16
Abstract 3476: TAK-243 increases tumor immunogenicity enhancing systemic anti-tumor immune response and tumor regression in combination with immune checkpoint inhibition in a syngeneic model of lymphoma
20230 citationsauthor #1
Multiplexed trackable intratumor microdosing of the investigational STING agonist TAK-676 alone and in combination in the native tumor microenvironment of patients with head and neck cancer: A phase 0 trial.
20232 citationsauthor #20
722 Evaluation of the effects of pembrolizumab alone and in combination(s) with MDSC-targeting agents MK-0482 and MK-4830 on the native cancer patient TME via functional spatial profiling (CIVO®)
20231 citationsauthor #22
Abstract 3424: Deep mechanistic profiling of immune oncology (I-O) drug combinations in cancer patients with CIVO® intratumoral microdosing and NanoString GeoMx DSP
20220 citationsauthor #7
Abstract CT216: A phase 0 master protocol utilizing a novel intratumoral microdosing approach for simultaneously evaluating multiple drugs and drug combinations in patients with solid tumors
20220 citationsauthor #17
A Novel Intratumoral Microdosing Approach for Simultaneously Evaluating Multiple Drugs and Combinations in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)
20220 citationsauthor #17
Abstract 620: Intratumoral microdosing via the CIVO® Platform reveals anti-tumor immune responses induced by the STING Agonist TAK-676 alone and in combination with chemotherapies
20221 citationsauthor #4
A Phase 0 Master Protocol Utilizing a Novel Intratumoral Microdosing Approach for Simultaneously Evaluating Multiple Drugs and Drug Combinations in Patients with Solid Tumors
20220 citationsauthor #16
Abstract CT139: Intratumoral (IT) microdosing of the investigational SUMOylation Inhibitor TAK-981 in a phase 0 CIVO trial demonstrates the reactivation of type I Interferon (IFN1) signaling in head and neck squamous cell carcinoma (HNSCC)
20221 citationsauthor #24
569 A CIVO intratumor microdose Phase 0 Trial of subasumstat (TAK-981) in combination with cetuximab or avelumab reveals Type 1 Interferon induction and immune activation in head and neck cancer patients
20220 citationsauthor #13
Abstract 1724: Microinjection of Nectin-4/CD137 tumor-targeted immune cell agonist (TICA™) activates the local tumor microenvironment
20210 citationsauthor #10
A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models
202198 citationsauthor #24
Multiplexed Evaluation of Microdosed Antineoplastic Agents In Situ in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma
202011 citationsauthor #17
Abstract 4136: Direct intratumoral microdosing via the CIVO® platform reveals anti-tumor immune responses induced by the SUMO inhibitor TAK-981
20191 citationsauthor #11
Abstract 2155: High-plex spatial profiling analysis of multidrug CIVO microdose studies in cancer patients
20190 citationsauthor #12
Multidrug analyses in cancer patients via intratumoral microdosing with CIVO: A microinjection technology for phase 0 drug investigation.
20181 citationsauthor #1
Abstract CT142: Multidrug analyses in cancer patients via intratumoral microdosing with CIVO: A functional approach to precision oncology
20180 citationsauthor #7
A modified gene trap approach for improved high-throughput cancer drug discovery
20184 citationsauthor #9
Establishment and characterization of a canine soft tissue sarcoma patient‐derived xenograft model
20175 citationsauthor #10
Abstract 4023: The SABRE platform: A novel, unbiased technology for drug discovery and prioritization
20170 citationsauthor #8
Multidrug Analyses in Patients Distinguish Efficacious Cancer Agents Based on Both Tumor Cell Killing and Immunomodulation.
201717 citationsauthor #23
Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition
20171 citationsauthor #13
Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition
201785 citationsauthor #13
Abstract 2835: Voruciclib, a clinical stage oral CDK inhibitor, sensitizes triple negative breast cancer xenografts to proteasome inhibition
20162 citationsauthor #8
Voruciclib Sensitizes High Risk Diffuse Large B Cell Lymphoma to BCL2 Inhibition Mediated Cell Death and Tumor Regression
20160 citationsauthor #10
A Platform for Rapid, Quantitative Assessment of Multiple Drug Combinations Simultaneously in Solid Tumors In Vivo
201610 citationsauthor #11
Minimally invasive in tumor multidrug comparative analysis with contrast‐enhanced MRI in mice
20160 citationsauthor #8
Abstract 2020: A platform to test multiple therapies simultaneously in the intact tumors of cancer patients: Initial clinical experience
20150 citationsauthor #8
Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration
2015102 citationsauthor #11
Abstract A39: A platform to assess multiple therapy options simultaneously in a patient's own tumor
20150 citationsauthor #1
Toxicity-sparing in-tumor profiling of multiple drugs simultaneously in canine patients with sarcoma.
20150 citationsauthor #9
Predicting responses to chemotherapy in the context that matters - the patient
20152 citationsauthor #3
A technology platform to assess multiple cancer agents simultaneously within a patient’s tumor
201581 citationsauthor #1
articleA gene expression signature of RAS pathway dependence predicts response to PI 3 K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors
20151 citationsauthor #3
Combination of themTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial
20143 citationsauthor #15
Abstract 3129: A platform to assess multiple therapy options simultaneously in a patient's own tumor
20140 citationsauthor #1
Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial
201453 citationsauthor #14
105 A platform to test multiple therapy options simultaneously in a patient's own tumor
20140 citationsauthor #2
Abstract 4153: Arrayed microinjection of a ubiquitin activating enzyme inhibitor induces PD biomarker effects predictive ofin vivotumor responses to systemic drug delivery.
20130 citationsauthor #8
Abstract 5116: Identification and rapidin vivovalidation of a novel drug combination for treating melanoma
20120 citationsauthor #7
Protein tyrosine phosphatase epsilon affects body weight by downregulating leptin signaling in a phosphorylation-dependent manner.
201151 citationsauthor #8
articleA gene expression signature of RAS pathway dependence predicts response to PI 3 K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors
2010147 citationsauthor #3
Reduced seed region-based off-target activity with lentivirus-mediated RNAi.
201026 citationsauthor #1
Pathway-Based Identification of Biomarkers for Targeted Therapeutics: Personalized Oncology with PI3K Pathway Inhibitors
2010160 citationsauthor #11
A Lentivirus-Mediated Genetic Screen Identifies Dihydrofolate Reductase (DHFR) as a Modulator of β-Catenin/GSK3 Signaling
200918 citationsauthor #1
An Optimized Lentivirus-Mediated RNAi Screen Reveals Kinase Modulators of Kinesin-5 Inhibitor Sensitivity
20088 citationsauthor #1
Advancing cancer target discovery through vector-mediated RNAi.
20060 citationsauthor #2
Evolutionary Divergence of Platelet-Derived Growth Factor Alpha Receptor Signaling Mechanisms
2003400 citationsauthor #2
CHAPTER 261 – PDGF Receptor Signaling in Mouse Development
20030 citationsauthor #1
Src Catalytic but Not Scaffolding Function Is Needed for Integrin-Regulated Tyrosine Phosphorylation, Cell Migration, and Cell Spreading
2002150 citationsauthor #2
An allelic series at the PDGFalphaR locus indicates unequal contributions of distinct signaling pathways during development.
2002203 citationsauthor #1
The two PDGF receptors maintain conserved signaling in vivo despite divergent embryological functions.
2001158 citationsauthor #1
Retention of PDGFR- (cid:1) function in mice in the absence of phosphatidylinositol 3 (cid:1) -kinase and phospholipase C (cid:2) signaling pathways
20003 citationsauthor #2
Src Family Kinases Negatively Regulate Platelet-derived Growth Factor α Receptor-dependent Signaling and Disease Progression*
200062 citationsauthor #4
Retention of PDGFR-beta function in mice in the absence of phosphatidylinositol 3'-kinase and phospholipase Cgamma signaling pathways.
200075 citationsauthor #2
Growth factor signaling pathways in vascular development
1999118 citationsauthor #3
PDGF induces an early and a late wave of PI 3-kinase activity, and only the late wave is required for progression through G1.
1999151 citationsauthor #2
Compartmentalized signaling by GPI-anchored ephrin-A5 requires the Fyn tyrosine kinase to regulate cellular adhesion.
1999324 citationsauthor #4
Src family kinases are required for integrin but not PDGFR signal transduction
1999775 citationsauthor #1
Effects of overexpressing wild-type and mutant PDGF receptors on translocation of GLUT4 in transfected rat adipose cells.
199631 citationsauthor #7
Platelet-derived growth factor-dependent activation of phosphatidylinositol 3-kinase is regulated by receptor binding of SH2-domain-containing proteins which influence Ras activity
1996138 citationsauthor #1
Identification of a Putative Syp Substrate, the PDGFβ Receptor (*)
1995162 citationsauthor #1

TIMELINE

1995 162 citations

1996 169 citations

1999 1,368 citations

2000 140 citations

2001 158 citations

2002 353 citations

2003 400 citations

2006 0 citations

2008 8 citations

2009 18 citations

2010 333 citations

2011 51 citations

2012 0 citations

2013 0 citations

2014 56 citations

2015 186 citations

2016 12 citations

2017 108 citations

2018 5 citations

2019 1 citations

2020 11 citations

2021 98 citations

2022 2 citations

2023 22 citations

2024 2 citations

2025 0 citations

R. Klinghoffer

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT